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Abstract
Background: Dominant mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most prevalent cause of
Parkinson’s disease, however, little is known about the biological function of LRRK2 protein. LRRK2 is expressed in neural
precursor cells suggesting a role in neurodevelopment.
Methodology/Principal Findings: In the present study, differential gene expression profiling revealed a faster silencing of
pluripotency-associated genes, like Nanog, Oct4, and Lin28, during retinoic acid-induced neuronal differentiation of LRRK2-
deficient mouse embryonic stem cells compared to wildtype cultures. By contrast, expression of neurotransmitter receptors
and neurotransmitter release was increased in LRRK2+/2 cultures indicating that LRRK2 promotes neuronal differentiation.
Consistently, the number of neural progenitor cells was higher in the hippocampal dentate gyrus of adult LRRK2-deficient
mice. Alterations in phosphorylation of the putative LRRK2 substrates, translation initiation factor 4E binding protein 1 and
moesin, do not appear to be involved in altered differentiation, rather there is indirect evidence that a regulatory signaling
network comprising retinoic acid receptors, let-7 miRNA and downstream target genes/mRNAs may be affected in LRRK2-
deficient stem cells in culture.
Conclusion/Significance: Parkinson’s disease-linked LRRK2 mutations that associated with enhanced kinase activity may
affect retinoic acid receptor signaling during neurodevelopment and/or neuronal maintenance as has been shown in other
mouse models of chronic neurodegenerative diseases.
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Introduction
Parkinson’s disease (PD) is the most prevalent movement
disorder and is neuropathologically characterized by the selective
loss of dopaminergic neurons in the substantia nigra related to
motor dysfunction. Although the etiology of PD is incompletely
understood, genetic studies have identified mutations in several
genes that segregate with rare familial forms of the disease [1].
Mutations in the PARK8 gene encoding leucine-rich repeat kinase
2 (LRRK2) are the most prevalent cause of autosomal dominantly
inherited PD and are characterised by typical brainstem Lewy
body pathology. The most frequent mutation, LRRK2(G2019S),
is found in the DF/YG motif of the kinase domain and is
responsible for approximately 1% of sporadic PD and 5% of
familial cases in Caucasians. LRRK2 is a 286 kDa protein
containing an N-terminal leucine-rich repeat, a Ras of complex
protein (Roc) GTPase domain, a C-terminal of Roc (Cor) region, a
kinase domain, and a WD40 protein interaction domain. Several
studies demonstrated that the G2019S mutation enhances kinase
activity in vitro and that kinase activity mediates degeneration in
transfected neurons [2,3].
LRRK2 protein shows widespread, neuronal-specific expression
in the adult mammalian brain [4]. Unexpectedly, LRRK2 knock-
out mice do not exhibit any alterations in neuronal function or
survival [5]. Therefore, the physiological function of LRRK2 in
neurons remains enigmatic. Prominent LRRK2 expression has
been detected in the subventricular zone and in the hippocampal
dentate gyrus of the mouse brain suggesting a role of LRRK2 in
neurogenesis [6,7]. In the present study, wildtype and LRRK2-
deficient mouse embryonic stem (ES) cells were used to investigate
the effects of LRRK2 on neuronal differentiation.
Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM), RPMI 1640, ES
cell medium and fibroblast medium ingredients were obtained
from Gibco (Invitrogen, Karlsruhe, Germany). Leukaemia inhib-
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bach, Germany). Poly-D-lysine, gelatine, stocks for N2 and
Complete medium, retinoic acid, mitomycin C, and EDTA were
all obtained from Sigma (Steinheim, Germany). Laminin was
supplied by Roche (Mannheim, Germany). Penicillin-streptomycin
was purchased from Cambrex (North Brunswick, NJ, USA).
Unless noted otherwise, all primary antibodies and all horseradish
peroxidase-linked secondary antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA). The rabbit anti-
GluR5 antibody was supplied by Upstate Biotechnology (Lake
Placid, NY, USA) and the mouse anti-GAPDH antibody was
obtained from Biotrend Chemicals (Cologne, Germany). The rat
anti-LRRK2 1E11 antibody was kindly provided by Prof. Marius
Ueffing, Helmholtz Center (Munich, Germany). The monoclonal
anti-stage-specific embryonic antigen-1 antibody was purchased
from R&D Systems (Wiesbaden, Germany). Alexa Fluor 568-
conjugated streptavidin was obtained from Invitrogen (Karlsruhe,
Germany).
Generation and differentiation of LRRK2+/2 mouse
embryonic stem cells
LRRK2 knock-out mice were custom-generated by Artemis
(Cologne, Germany) and will be described in detail elsewhere.
Briefly, C57/BL6N mouse embryonic stem (ES) cells were
transfected by electroporation, and homologous recombination
of the targeting vector at the exon 2 region of the mouse genomic
LRRK2 locus was verified by Southern blot analysis (Figure S1).
LRRK2 mRNA expression was analysed by quantitative RT-PCR
as described below. Since we wanted to exclude effects potentially
arising from the neomycin resistance cassette in the present cell
culture study, the marker was deleted after the selection of positive
ES cell clones.
ES cells were cultured and differentiated according to the
protocol previously described by others [8,9]. Briefly, ES cells were
cultured on mitomycin-inactivated mouse primary embryonic
fibroblast feeder cells (StemCell Technologies, Grenoble, France)
in ES cell medium (DMEM containing 15% (v/v) fetal bovine
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 0.1 mM 2-mercaptoethanol, and 2000 U/
ml leukaemia inhibitory factor) for at least two passages.
Subsequently, ES cells were deprived of feeder by three passages
on 0.2% gelatin-coated culture dishes in ES cell medium which
was exchanged daily. Embryoid bodies (EBs) were formed from
feeder-free ES cells grown as suspension culture on bacterial dishes
(Greiner Bio-One, Solingen, Germany) in EB medium (ES cell
medium lacking leukaemia inhibitory factor and containing 10%
fetal bovine serum) for 8 days. Medium was exchanged on day 2, 4
and 6 of EB culture. Neuronal differentiation was induced by
addition of 5 mM retinoic acid (RA) at day 4 and day 6 of EB
culture. At day 8, EBs were dissociated in 0.05% (w/v) trypsin
dissolved in phosphate-buffered saline (PBS) (AccuGene, Rock-
land, MA, USA) containing 0.04% (w/v) EDTA. Neural precursor
cells obtained from dissociated EBs were plated in a density of
2610
5 cells per cm
2 on dishes coated with poly-ornithin and
laminin in N2 medium containing DMEM and Ham’s nutrient
mixture F12 1:1 (v/v), L-glutamine (2 mM), insulin (25 mgm L
21),
transferrin (50 mgm L
21), progesterone (20 nM), putrescine
(100 nM), sodium selenite (30 nM) and bovine serum albumin
(BSA, 50 mgm L
21). Medium was exchanged after 2 and 24 hours
of plating. Forty-eight hours after plating of neural precursors,
medium was changed to Complete medium composed of DMEM
supplemented with alanin (2 mgm L
21), biotin (0.1 mgm L
21),
carnitin (2 mgm L
21), ethanolamine (1 mgm L
21), galactose
(15 mgm L
21), proline (7.8 mgm L
21), putrescine (16 mgm L
21),
sodium pyruvate (25 mgm L
21), sodium selenite (0.02 mgm L
21),
vitamin B12 (0.3 mgm L
21), zinc sulphate (0.2 mgm L
21), cata-
lase (2.6 mgm L
21), glutathione (1 mgm L
21), superoxide dismu-
tase (2.5 mgm L
21), linoleic acid (1 mgm L
21), linolenic acid
(1 mgm L
21), progesterone (6.3 ng mL
21), retinol (0.1 mgm L
21),
retinyl acetate (0.1 mgm L
21), tocopherole (1 mgm L
21), tocopher-
ole acetate (1 mgm L
21), BSA (2.5 mg mL
21), transferrin
(5 mgm L
21), insulin (4 mgm L
21) and L-glutamine (2 mM). The
medium was exchanged at day 4 of differentiation. At all stages of
ES cell differentiation the incubator settings were kept at 36.5uC,
7% CO2 and 90% humidity.
Protein extraction and Western blot analysis
At distinct stages of differentiation, cells were harvested in lysis
buffer including 30 mM Tris-HCl (pH 8.5), 4% (v/v) Chaps, 8 M
urea, and phosphatase inhibitor cocktail (Sigma, Germany).
Soluble protein supernatant fractions were obtained by centrifu-
gation 12,5006g for 10 minutes at 10uC. Proteins were separated
by SDS-PAGE and transferred to nitrocellulose membranes
(Protran, Whatman, Dassel, Germany). Membranes were routine-
ly checked for protein load and protein transfer using a protein
staining kit (MemCode, Pierce, Rockford, Illinois, USA) that
reversibly stains for total protein. Blots were blocked for 1 h in
Tris-buffered saline containing 0.1% (v/v) Tween-20 and 5% (w/
v) non-fat dry milk. Membranes were subsequently incubated over
night at 4uC with primary antibodies (1 mgm L
21). After repeated
washings with Tris-buffered saline/Tween-20 (0.1% v/v), mem-
branes were incubated for 1 h at room temperature with the
corresponding secondary antibody (0.5 mgm L
21). Antibody
binding was detected by enhanced chemiluminescence staining
(ECL Western blotting analysis system, GE Healthcare, Munich,
Germany) and exposure to X-ray films. Scanned Western blot
bands were quantified densitometrically and values were normal-
ized to the amount of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) using Quantity One software (Imaging Densitometer,
Model GS-700, Biorad, Munich, Germany).
RNA isolation
For total RNA isolation, ES cells splitted for 3 passages on
gelatine and ES cell-derived neurons differentiated for 7 days
(triplicate cultures of each genotype) were lysed in RLT buffer
provided by a ready-to-use RNA isolation kit (RNAeasy Kit,
Qiagen, Hilden, Germany). Sample homogenisation, total RNA
isolation and on-column DNase digest were performed according
to the manufacturer’s instruction. RNA concentration/purity was
determined on a spectrophotometer (NanoDrop ND-1000), and
RNA quantity/quality was analysed on a microfabricated chip
(RNA 6000 Nano LabChip kit, Agilent Technologies, Bo ¨blingen,
Germany). The RNA chip assay was executed on a microfluidics-
based platform (Agilent 2100 bioanalyzer) in accordance to the
manufacturer’s recommendation.
Microarray gene expression profiling
Gene expression profiling was performed using the GeneChip
Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s instruction. One-cycle
synthesis of double-stranded cDNA was done using 2 mgo f
isolated total RNA. After amplification and biotin-labelling of
cDNA followed by in vitro transcription, biotin-labeled cRNA was
purified, fragmented by heating and hybridized to the arrays
(triplicates for each genotype). Arrays were scanned using a
Hewlett-Packard GeneArray Scanner and data were analysed by
Affymetrix GeneChip software [10]. Data have been processed
with the R Language and Environment for Statistical Computing
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2.0 [11]. The Bioconductor affy package [12] has been used for
quality control and data were normalized using the robust multi-
array average (rma) [13] expression measure. Linear models [14]
as implemented in the Bioconductor limma package [15] were
applied to calculate fold changes, the resulting p-values were FDR-
corrected [16]. Genes showing $1.5-fold changes in expression
levels and an adjusted p-value,0.01 as a specific hybridization
signal were considered deregulated. Data are publicly available
from ArrayExpress database [17] (www.ebi.ac.uk/aerep/login),
experiment E-MEXP-2963. To analyze the enrichment of
deregulated gene transcripts in canonical pathways Ingenuity
Pathway Analysis 8.8. software (Ingenuity Systems, Redwood City,
Califormia, USA) was utilized. All genes that are differentially
regulated with a p-value,0.01 and an absolute fold change .1.5
when comparing LRRK2-deficient to wildtype cells were
considered for analysis. The significance of the association
between the gene transcript and the canonical pathway was
measured in two ways: First, a ratio of the number of molecules
from the data set that map to the pathway divided by the total
number of molecules that are annotated to the pathway was
calculated. Second, Fisher’s exact test was conducted to calculate a
p-value determining the probability that the association between
the genes in the dataset and the canonical pathway is explained by
chance alone.
Quantitative RT-PCR
Lab equipment and chemicals used for LRRK2 mRNA
expression level analyses were purchased from Applied Biosystems
(Darmstadt, Germany). Primer Express Software Version 3.0
assisted in the design of primers and probe. Expression levels of
mRNA were quantified via one-step RT-PCR (TaqMan) in a
10 mL reaction containing QuantiTect Probe RT-PCR Mast-
er Mix (Qiagen, Hilden, Germany), forward and reverse primer
(0.4 mM each), 59 fluorescence-labelled probe (0.2 mM), Quanti-
Tect Multiplex RT Mix (0.5 mL per reaction, Qiagen, Hilden,
Germany) and RNA template (100 ng). The following primer and
probes were applied: mouse LRRK2-forward (ACATGCTGG-
TGTTCACCTACTC), mouse LRRK2-reverse (CAACAGAGG-
CACGTGGAAATTTT), mouse LRRK2-probe (59 FAM-labelled
MGB probe, ACCGCGCCTCCAAGTT). The reaction was
carried out in optical 96 well-plates. The thermocycler (7500 Fast
Real-Time PCR System, 7500 Fast System Software v1.3.1) was
programmed for reverse transcription (30 min at 48uC), a single
denaturation step (10 min at 95uC) and 40 amplification cycles
(15 s at 95uC cDNA denaturation, 60 s at 60uC combined
annealing/extension and fluorescence data collection step). Real-
Time PCR was carried out in triplicate for each marker and
sample.
Immunocytochemistry
Cells grown either on Lab-Tek chamber slides (Nunc,
Wiesbaden, Germany) or 96-well plates (Becton Dickinson,
Heidelberg, Germany) were fixed in ice-cold paraformaldehyde
(4%) for 10 min, washed in PBS and blocked for 1 h in PBS
containing 1% BSA and 0.1% saponin (Sigma, Steinheim,
Germany). Cells were then incubated with primary antibodies
(1 mgm L
21) in blocking solution over night at 4uC. After washing
with PBS, cells were incubated with the secondary antibodies
(5 mgm L
21) for 1 h at 37uC. When working with the biotin-
streptavidin system, cells were again rinsed with PBS and then
incubated for 1 h at 37uC with Alexa Fluor-568 conjugated
streptavidin (Invitrogen, Karlsruhe, Germany). After washing with
PBS, cells were mounted in Confocal Matrix (Micro-Tech-Lab,
Graz, Austria). Stainings for alkaline phosphatase were performed
using a commercially-available detection kit (Chemicon/Millipore,
Schwalbach, Germany) according to the manufacturer’s protocol.
Images were collected on an inverted microscope (Axiovert 135,
Zeiss, Goettingen, Germany). Alternatively, cells were imaged
using a Becton Dickinson Pathway 435 imager and evaluated
using AttoVision 1.5 software (Becton Dickinson Biosciences,
Rockville, Maryland, USA).
Kinase assay in solution
N-terminal GST-tagged human LRRK2 (amino acids 970-
2527) (Invitrogen, Carlsbad, California, USA) was incubated in
kinase reaction buffer (25 mM Tris, pH 7.5, 10 mM MgCl2,
0.1 mM EGTA, 2 mM dithiothreitol, 1 mM sodium orthovana-
date) containing 100 mM ATP and 30 mCi [c-
33P]ATP at 30uC for
45 minutes. The enzyme reaction was stopped by the addition of
46 Laemmli buffer (4% sodium dodecyl sulfate, 400 mM
dithiothreitol, 200 mM Tris, pH 7.5). Proteins were heated for
10 minutes to 70uC, and separated on 4–12% NuPAGE Bis-Tris
gradient minigels. Gels were dried for 30 minutes at 70uCi na
vacuum gel dryer (Model 583, Bio-Rad, Munich, Germany) and
exposed to phosphoscreens over night. Phosphoscreens were
imaged on a Typhoon 9400 laser scanner (GE Healthcare,
Freiburg, Germany) and quantitated using Quantity One (Bio-
Rad, Munich, Germany). Phosphosite mapping of recombinant
retinoic acid receptor alpha was performed by NextGen Sciences
(Ann Arbor, Michigan, USA) as has been described elsewhere
[18]. Recombinant full-length retinoic acid receptor alpha and
retinoic acid receptor beta was purchased from Abnova (Taipei,
Taiwan) and tested at the concentrations indicated in the Results
section.
Neurotransmitter release
For measurement of depolarisation-induced neurotransmitter
release, ES cell-derived neurons differentiated for 7 days (triplicate
cultures of each genotype) were cultured in medium containing
80 mM KCl for 3 min. The medium was harvested in ice-cold
0.1 M perchloric acid and stored at 280uC. GABA and glutamate
content were analysed by HPLC and electrochemical detection at
Brains On-Line (Groningen, Netherlands) using published proto-
cols (www.brainsonline.org).
Hippocampal neurogenesis in LRRK2-deficient mice
All animal experiments were carried out in accordance with the
National Institutes of Health guidelines for the treatment of
laboratory animals and the European Communities Council
Directive (86/609/EEC) and were approved by the local
governmental commission for animal health. To label proliferating
hippocampal stem cells, BrdU (100 mg/kg body weight) was
administered to LRRK2 knockout mice and wildtype littermate
controls (n=6 per group) by a single intraperitoneal injection.
After 24 hours animals were deeply anaesthetized and transcar-
dially perfused with 0.9% NaCl followed by 4% paraformaldehyde
in 0.1 M phosphate-buffered saline (PBS) (pH 7.4). Brains were
removed, postfixed overnight in 4% paraformaldehyde at 4uC,
and stored in 30% sucrose in 0.1 M PBS at 4uC. To label
surviving/differentiating hippocampal progenitor cells, BrdU was
administered to a second goup of mice (n=6 per genotype) from
day 1 to day 5 by daily intraperitoneal injections (50 mg/kg body
weight). Anaesthetized animals were perfused on day 28 of
treatment and brains were processed as described above.
Immunohistochemical analysis was performed as has been
published elsewhere [19]. Brains were cut into 25 mm coronal
sections. For BrdU immunostaining free-floating sections were
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ter, sections were incubated with 0.6% H2O2, blocked in 3%
donkey serum, and permeabilised with 0.1% Triton-X100. The
sections were incubated with either a rat monoclonal anti-BrdU
antibody (1:500, AbD Serotec, Oxford, UK) or a goat polyclonal
anti-doublecortin (DCX) antibody (1:500; Santa Cruz Biotechnol-
ogy, Santa Cruz, California, USA). Brain sections were subse-
quently incubated with a biotinylated secondary antibody (1:1000)
followed by avidin-biotin-peroxidase complex (1:100) and diami-
nobenzidine as substrate (Vector Laboratories, Burlingame,
California, USA). Sections were mounted on Superfrost Plus
slides (Menzel, Braunschweig, Germany) in Neo Mount medium
(Merck, Darmstadt, Germany). All counting procedures were
performed on coded slides. To count BrdU- and DCX-immuno-
positive cells, every 6th hippocampal section was analysed using a
light microscope (AxioImager M2, Zeiss, Jena, Germany)
equipped with a semi-automatic stereology system (Stereoinvesti-
gator, MicroBrightField, Magdeburg, Germany). The total
number of positive cells per dentate gyrus was calculated using
the optical dissector method [20]. Control stainings where the
primary antibody was omitted produced no signal.
Statistical analysis
All experiments were performed using at least three biological
replicates. Mean values 6 standard deviations are indicated in the
Results section. Statistical significance was determined by two-
tailed Student’s t-test. A p-value,0.05 was considered significant.
Results
Characterisation of LRRK2+/2 murine embryonic stem
cells during neuronal differentiation
By homologous recombination of the targeting vector at the
exon 2 region of the mouse genomic LRRK2 locus, heterozygous
LRRK2+/2 C57BL/6N mouse embryonic stem (ES) cells were
generated. Two ES cell clones, where homologous recombination
was verified by Southern blot analysis (Figure S1), were used for
further characterisation. Quantitative RT-PCR revealed a signif-
icant reduction of LRRK2 mRNA levels to 55.964.3% compared
to wildtype C57BL/6N ES cells. We also analysed expression
levels of LRRK2 protein at different stages of neuronal
differentiation by Western blotting using a validated anti-LRRK2
antibody. Densitometric quantification of the 275 kDa full-length
Figure 1. Western blot analysis of LRRK2 protein levels in cell
lysates. (A) LRRK2 (and one fragment) is expressed in cultured mouse
embronic stem cells (ESC), and its expression increases during retinoic
acid-induced neuronal differentiation. LRRK2 levels in LRRK2+/2 cells
are about 50% lower than in wildtype (wt) cells. Levels of glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) were co-detected as gel
loading controls and indicate that lower protein amounts were loaded
in the LRRK2+/2 ESC-derived neuron sample. The immunoblots shown
are representative of three independent experiments. (B) Full-length
LRRK2 protein bands were quantified by densitometry and normalized
to GAPDH loading control using Quantity One software. Bars represent
mean 6 SD (n=3).
doi:10.1371/journal.pone.0020820.g001
Figure 2. Immunocytochemical and morphological analysis of
LRRK2+/2 (right panels) and wildtype (left panels) ES cells
during neuronal differentiation. (A, B) Undifferentiated ES cells on
fibroblast feeders are immunoreactive for the pluripotency marker
stage-specific embryonic antigen-1. (C, D) Embryoid bodies grown in
suspension culture show similar morphology. (E, F) At differentiation
day 7, ES cell-derived neurons immunostained for b-III tubulin exhibit
similar cell densities and neurite networks.
doi:10.1371/journal.pone.0020820.g002
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cultured murine ES cells (Figure 1). Protein levels significantly
increased in embryoid bodies and remained elevated in ES cell-
derived neurons. In line with the LRRK2 mRNA data mentioned
above, LRRK2 protein levels in LRRK2+/2 cells were about
50% lower than in wildtype cells at all stages (Figure 1).
Transduction of LRRK2-deficient embryonic ES cells with an
adenoviral type 5 expression vector in order to reconstitute
LRRK2 expression caused cell death as has been shown in other
cell culture models overexpressing LRRK2 (data not shown).
Pluripotency of LRRK2+/2 and wildtype ES cells was
confirmed both by detection of high alkaline phosphatase activity
[18] and by immunostaining for the surface marker stage-specific
embryonic antigen-1 (SSEA-1) (Figure 2 A, B). During all steps of
differentiation no obvious differences in cell density or morphology
could be observed between LRRK2+/2 and wildtype cells by
microscopical imaging and digital analysis (Figure 2). Immuno-
staining for neuron-specific b-III tubulin and nuclear Hoechst
33342 labelling revealed that about 95% of both LRRK2+/2 and
wildtype cells adopted a neuronal phenotype after retinoic acid
treatment for 7 days (Figure 2) [18]. Neuronally-differentiated ES
cells cultured for .7 days exhibited neurite blebbing precluding
longer observation times.
Microarray gene expression analysis
To get more insight into the cellular function of LRRK2, we
performed differential gene expression profiling using RNA
samples from undifferentiated, SSEA1-immunopositive ES cells
and from differentiated, b-III tubulin-immunoreactive ES cell-
derived neurons, respectively. As shown in Figure 3, only 9 genes
were significantly (fold change $1.5 and adjusted p-value#0.01)
down-regulated and 14 genes were up-regulated in LRRK2+/2
ES cells compared to wildtype controls. By contrast, 7 days after
starting retinoic acid-induced differentiation, 2404 genes were
significantly down-regulated and 575 genes were up-regulated in
LRRK2+/2 ES cell-derived neurons compared to wildtype
cultures. Similar changes were detected when two clones (A, B)
with monoallelic LRRK2 deletion were compared to wildtype ES
cell-derived neurons, whereas gene expression did not differ
between the LRRK2+/2 clones A and B (Figure 3). The complete
Genechip dataset has been loaded into ArrayExpress database
(www.ebi.ac.uk/aerep/login) under experiment E-MEXP-2963.
These findings indicate that LRRK2 adopts a critical biological
function during retinoic acid-induced neuronal differentiation,
although LRRK2 is already expressed at the ES cell stage.
Notably, mRNA expression of the key pluripotency transcrip-
tion factors Nanog, Lin28, and Oct4 (also termed Oct3 and
Figure 3. Affymetrix GeneChip analysis comparing mRNA expression levels in: (A) clone A LRRK2+/2 ES cells versus wildtype ES
cells, (C) clone A LRRK2+/2 ES cell-derived neurons versus wildtype ES cell-derived neurons, (D) clone B LRRK2+/2 ES cell-derived
neurons versus wildtype ES cell-derived neurons, and (B) clone A LRRK2+/2 ES cell-derived neurons versus clone B LRRK2+/2 ES
cell-derived neurons. Massive changes in gene expression become detectable in LRRK2+/2 ES cell-derived neurons compared to wildtype ES cell-
derived neurons 7 days following neuronal differentiation by retinoic acid administration.
doi:10.1371/journal.pone.0020820.g003
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after retinoic acid-induced neuronal differentiation (Table 1).
Moreover, expression of pluripotency-linked, downstream target
genes of Nanog and Oct4 in ES cells, like developmental
pluripotency-associated protein, left-right determination factor 2,
secreted phosphoprotein, F-box protein-15, and zinc-finger
protein-42 [21,22], declined as well (Table 1). On the other hand,
genes that are transcriptionally repressed by Nanog/Oct4 and that
promote differentiation (e.g. homeobox B5, homeobox A4,
Pou4f2) showed a moderate increase in expression in LRRK2+/
2 ES cell-derived neurons (Table 1) suggesting that differentiation
may be accelerated in retinoic acid-treated LRRK2+/2 ES cells.
Consistently, mRNA levels of various ion channels and neuro-
transmitter receptors, like voltage-gated sodium channel Scn1a,
voltage-gated potassium channel Kcnq2, metabotropic glutamate
receptor 8, and ionotropic glutamate receptor 1, were significantly
higher in LRRK2+/2 neurons (Table 1). Messenger RNA
expression of glial markers (e.g. glial fibrillary acidic protein) did
not differ between LRRK2+/2 and wildtype cell cultures
indicating that there is no redirection in differentiation from
neuronal to glial lineages. Ingenuity canonical pathway analysis
also points to an enrichment of gene transcripts annotated to stem
cell pluripotency, cell cycle regulation, and neuronal function
(Figure S2).
The actin-binding proteins ezrin/radixin/moesin and the
translational repressor eukaryotic translation initiation factor 4E
binding protein 1 (4E-BP1) have been identified as LRRK2
substrates in vitro [23,24]. Our Genechip analysis revealed that
mRNA expression of moesin and 4E-BP1 was significantly down-
regulated in LRRK2+/2 ES cell-derived neurons (Table 1).
Western blot analysis
In order to confirm alterations in mRNA expression on the
protein level, protein extracts from cultured cells were assessed by
Western blotting. The pluripotency transcription factor Nanog
was still detectable in extracts from wildtype neurons 7 d after
retinoic acid-induced differentiation, whereas Nanog protein was
not detected in LRRK2+/2 neurons (Figure 4). On the other
hand, protein levels of the ionotropic glutamate receptor 5 were
significantly increased by 117.569.1% (Figure 5). Additionally,
Western blotting revealed a decline in ezrin/radixin/moesin
protein levels by 52.366.1% (Figure 6) and in 4E-BP1 by
81.067.7% in LRRK2+/2 ES cell-derived neurons, whereas
protein expression of eukaryotic translation initiation factor 4E
(eIF4E), the interaction partner of 4E-BP1, remained unaltered
(Figure 5).
Since LRRK2 has been shown to phosphorylate ezrin/radixin/
moesin on a conserved threonine residue (Thr588 in moesin) and
4E-BP1 on threonine 70 [23,24], we used phospho-specific
antibodies to investigate alterations in their phosphorylation status
in LRRK2+/2 neurons derived from ES cells. Unexpectedly,
neither the ratio of phospho-ezrin/radixin/moesin(Thr588) to
total ezrin/radixin/moesin nor the ratio of phospho-4E-
BP1(Thr70) to total 4E-BP1 showed a significant decrease in
LRRK2+/2 neurons indicating that LRRK2 is not rate-limiting
for phosphorylation in our cell culture model (Figures 5 and 6).
Table 1. Differentially-expressed genes in LRRK2+/2 versus wildtype embryonic stem cell-derived neurons.
SYMBOL ACCESSION GENE fold change adj. p-value
Nanog NM_028016.2 Nanog homeobox 244.359 1.3E-07
Pou5f1 NM_013633.2 POU domain, class 5, transcription factor 1 234.983 2.2E-08
Spp1 NM_009263.1 secreted phosphoprotein 1 223.884 2.8E-09
Lin28 NM_145833.1 lin-28 223.555 7.1E-09
Dppa2 NM_028615.1 developmental pluripotency associated 2 215.776 1.8E-08
Lefty2 NM_177099.3 Left-right determination factor 2 214.112 2.4E-07
Eif4ebp1 NM_007918.3 eukaryotic translation initiation factor 4E binding protein 1 28.790 2.2E-08
Rai14 NM_030690.2 retinoic acid induced 14 25.756 4.8E-07
Crabp2 NM_007759.2 cellular retinoic acid binding protein II 23.166 1.9E-06
Msn NM_010833.2 moesin 22.579 1.7E-06
Slc1a6 NM_009200.2 solute carrier family 1 (aspartate/glutamate transporter) 1.517 2.6E-03
Cend1 NM_021316.3 cell cycle exit and neuronal differentiation 1 1.530 1.8E-04
Snca NM_009221.2 synuclein, alpha 1.598 1.3E-04
Slc6a11 NM_172890.3 solute carrier family 6 (neurotransmitter transporter, GABA) 1.612 6.3E-05
Kcnma1 NM_010610.2 potassium large conductance calcium-activated channel 1.614 7.8E-04
Gabbr1 NM_019439.3 gamma-aminobutyric acid (GABA-B) receptor, 1 1.631 2.8E-05
Syn2 NM_013681.1 synapsin II 1.634 3.6E-05
Cacna2d3 NM_009785.1 calcium channel, voltage-dependent, alpha2/delta subunit 3 1.821 3.0E-06
Grm8 NM_008174.2 glutamate receptor, metabotropic 8 1.845 6.8E-06
Grik1 NM_010348.2 glutamate receptor, ionotropic, kainate 1 2.073 2.1E-05
Nrn1 NM_153529.1 neuritin 1 2.134 6.3E-06
Sncg NM_011430.2 synuclein, gamma 2.266 1.1E-05
Calb2 NM_007586.1 calbindin 2 2.396 4.0E-06
doi:10.1371/journal.pone.0020820.t001
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of protein were loaded per lane (Figure S3).
Retinoic acid receptor signaling
Gene expression profiling also provided a first hint that retinoic
acid signaling may be altered in LRRK2+/2 neurons during
differentiation from ES cells. As shown in Table 1, several retinoic
acid receptor target genes (e.g. retinoic acid induced 14, stimulated
by retinoic acid gene 8, cellular retinoic acid binding protein 2)
were differentially expressed, while mRNA levels of retinoic acid
receptors alpha and beta were unaltered. Transcriptional
regulation by retinoic acid receptors is modulated by various
kinases (e.g. MAP kinases) through receptor phosphorylation
thereby modulating binding to coactivators, repressors, or DNA
[25]. This led us to investigate whether LRRK2 is able to
phosphorylate retinoic acid receptors in vitro and to compare
efficiency of phosphorylation of retinoic acid receptor to moesin
and tubulin-beta 2C which are potently phosphorylated by
recombinant LRRK2 [18]. Using threefold dilutions of each
recombinant protein substrate we observed that retinoic acid
receptors alpha (Figure 7 A, B) and beta (not shown) become
phosphorylated by LRRK2 as efficiently as moesin and tubulin-
beta 2C, respectively. As a negative control, kinase-dead
LRRK2(D1994A) did not phosphorylate either protein under
the same assay conditions (Figure 7C). By tandem mass
spectrometry one phosphorylated peptide (DGGGLAPPPGSCS-
PSLSPSSNR) was detected in a tryptic digest of retinoic acid
receptor alpha (63% sequence coverage), and serine-445 was
identified as phosphorylation site.
Neurotransmitter levels
To demonstrate biological relevance of the increased expression
of neuronal markers in LRRK2+/2 ES cell-derived neurons, we
assessed neurotransmitter release during potassium-induced depo-
larisation. Neurotransmitter concentrations in the cell culture
medium were analysed by HPLC and normalised to protein
amounts in ES cell lysates. GABA concentrations were signifi-
cantly higher in LRRK2+/2 neuronal cultures compared to
wildtype controls (82.063.3 versus 58.362.8 nmol/g protein,
LRRK2-deficient versus wildtype cultures, mean 6 SD, n=3
each), and glutamate concentrations showed a trend towards an
Figure 4. Western blot analysis of Nanog protein levels in cell
lysates. (A) Protein expression of the pluripotency marker Nanog
decreases more rapidly during retinoic acid-induced neuronal differen-
tiation in LRRK2+/2 cells. Levels of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were co-detected as gel loading controls.
The immunoblots shown are representative of three independent
experiments. (B) Nanog immunoreactive bands were quantified by
densitometry and normalized to GAPDH loading control. Bars represent
mean 6 SD (n=3). Asterisk (*) indicates statistical significant (p,0.05)
difference.
doi:10.1371/journal.pone.0020820.g004
Figure 6. Protein expression and phosphorylation of the
putative LRRK2 substrate proteins ezrin, radixin, and moesin
(ERM). Immunoreactive bands are reduced in LRRK2+/2 ES cell-derived
neurons (lane 4–6) compared to wildtype cultures (lane 1–3). Levels of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are shown as gel
loading controls. Three replicate cultures per genotype were analysed.
For densitometric quantification see Results section.
doi:10.1371/journal.pone.0020820.g006
Figure 5. Protein expression and phosphorylation of the
putative LRRK2 substrate 4E binding protein 1 (4E-BP1). Both
signals decline in LRRK2+/2 ES cell-derived neurons (lane 4–6)
compared to wildtype cultures (lane 1–3). Protein levels of eukaryotic
translation initiation factor 4E (eIF4E), the interaction partner of 4E-BP1,
are unchanged. Protein expression of the ionotropic glutamate receptor
5 (GluR5) is increased in LRRK2+/2 neurons (lane 4–6) compared to
wildtype cells (lane 1–3). Three replicate cultures per genotype were
analysed. For densitometric quantification see Results section.
doi:10.1371/journal.pone.0020820.g005
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further substantiate an accelerated neuronal differentiation in
retinoic acid-treated LRRK2+/2 ES cells.
Hippocampal neurogenesis in adult LRRK2-deficient mice
To analyse the impact of LRRK2 deficiency on neuroge-
nesis in vivo, we investigated proliferation and differentiation of
hippocampal stem cells in the subgranular zone of the dentate
gyrus of adult mice. The number of proliferating BrdU-labeled
hippocampal stem cells did not differ between LRRK2 knock-out
mice and wildtype littermate controls. Moreover, the number of
surviving BrdU-positive hippocampal stem cells that can be
detected 28 days after systemic BrdU administration showed no
significant difference (data not shown). Importantly, by counting
the numbers of neuroblasts expressing the early neuronal
maturation marker doublecortin (DCX) we detected a significant
(p,0.05) increase in the total number of DCX-immunopositive
cells in the dentate gyrus of LRRK2 knockout mice compared to
wildtype controls (42976325 versus 28916203 DCX-positive
cells, mean 6 SEM).
Discussion
Prominent LRRK2 expression has been detected in the
ventricular and subventricular zones as well as in the hippocampal
formation of the embryonic and adult mouse brain. LRRK2
mRNA was also expressed in neurosphere cultures consisting of
neuronal stem cells and precursor cells suggesting a role of
LRRK2 in neurogenesis or in neurodevelopment [6,7]. In the
present study, wildtype and LRRK2+/2 primary mouse ES cells
were cultured followed by retinoic acid treatment to induce
neuronal differentiation. This cell culture model has already been
used to assess the effects of a-synuclein overexpression and
amyloid precursor protein deficiency, respectively, on neuronal
development [26,27]. By immunocytochemical staining and
microscopic evaluation no obvious differences in cell viability,
Figure 7. Retinoic acid receptor alpha is efficiently phosphor-
ylated by recombinant LRRK2. (A) Autoradiogram demonstrating
phosphorylation of recombinant tubulin-beta 2C (lane 1–3), heat-
treated meosin (lane 4–6), and retinoic acid receptor alpha (lane 7–9) by
recombinant LRRK2(G2019S) (amino acids 970-2527). Three-fold dilu-
tions of each recombinant protein were incubated with kinase and
[c-
33P]ATP for 45 min. (B) Coomassie Blue protein post-staining of the
gel. (C) (Left panel) Kinase-dead LRRK2(D1994A) does not autopho-
sphorylate or phosphorylate retinoic acid receptor alpha (lane 2)
compared to active LRRK2(G2019S) (lane 1). (Right panel) Similar
protein amounts are detected by Coomassie Blue protein staining.
doi:10.1371/journal.pone.0020820.g007
Figure 8. Model of how LRRK2-deficiency may promote retinoic-acid induced neuronal differentiation. Lin28 protein and let-7 miRNA
are key regulators of pluripotency and differentiation, respectively. Lower protein levels of LRRK2 and 4E-BP1 in LRRK2+/2 ES cells may alleviate
suppression of let-7 miRNA function by LRRK2. LRRK2 may also phosphorylate retinoic acid receptors, thereby modulating transcriptional activation/
repression of differentiation/stemness factors (for details see Discussion).
doi:10.1371/journal.pone.0020820.g008
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gene expression analysis however, revealed significant changes
following retinoic acid-induced differentiation. The ES cell
genome is transcriptionally hyperactive and undergoes large-scale
silencing as cells differentiate [28] which was more prominent in
the LRRK2+/2 neural precursor cells. Notably, the central
regulators of ES cell pluripotency, Lin28, Nanog, and Oct4, and
several of their downstream pluripotency-linked target genes
[21,22] declined more rapidly in LRRK2+/2 cells. On the other
hand, expression of various voltage-gated ion channels and
neurotransmitter receptors/transporters was increased in
LRRK2-deficient neural precursor cells. Since both glutamatergic
and GABAergic markers were upregulated to a similar extent, our
data point to an acceleration of neuronal differentiation, and not
to a change in neuronal phenotype in LRRK2+/2 cells. Subtle
phenotypic changes however, can only be excluded after extensive
electrophysiological characterisation of the ES cell-derived neu-
rons. Increased medium concentrations of GABA and glutamate
in LRRK2+/2 cell cultures may merely confirm accelerated
neuronal differentiation. Non-synaptic GABA however, acts as a
developmental signal on neural precursor cells promoting
differentiation and maturation [29] which may also constitute a
positive feedback loop in our cell culture system.
What may be the underlying mechanism for LRRK2
deficiency-mediated alterations in neuronal differentiation?
LRRK2 phosphorylates moesin which regulates binding to F-
actin, cytoskeletal stability, and neurite sprouting [23,30,31].
Moreover, actin cytoskeleton stability influences stem cell
differentiation in culture [32,33]. Moesin phosphorylation how-
ever, was unchanged in LRRK2-deficient differentiating neurons
making a contribution unlikely. Since gene expression changes
were most pronounced following retinoic acid treatment and since
several genes containing retinoic acid response elements (e.g.
Stra8, Rai14) were affected, we hypothesized that retinoic acid
signaling may be altered in LRRK2+/2 cells. In response to
retinoic acid, mitogen-activated protein (MAP) kinases become
activated which phosphorylate retinoic acid receptors, thereby
modulating transcriptional activity and proteasomal degradation
[25]. The kinase domain of LRRK2 exhibits sequence homology
to the MAP kinase kinase kinase family, and there is in vitro
evidence that LRRK2 acts within MAP kinase signaling cascades
[34]. We could demonstrate that recombinant LRRK2 potently
phosphorylates retinoic acid receptors in vitro indicating that
LRRK2 may directly modulate its function (Figure 8). Cellular
assays using retinoic acid-responsive element containing reporter
genes are required to analyse the functional consequences
in vivo.
Very recently, LRRK2 has been shown to antagonize let-7
miRNA-mediated translational repression in mature Drosophila
neurons leading to neurodegeneration [35]. LRRK2 protein
suppressed the inhibitory effects of let-7 miRNA by promoting the
interaction of phosphorylated 4E-BP1 with Argonaute. In
embryonic stem cells, let-7 miRNA acts as a key pro-differenti-
ation factor by blocking mRNA translation of pluripotency factors,
like Lin28, Sall4, and Hmga2 [36,37]. In the self-renewing state,
the RNA-binding protein Lin28 inhibits processing and matura-
tion of let-7 miRNA. Administration of retinoic acid causes a
repression of Lin28 mRNA and an upregulation of let-7 miRNA
and a concomitant switch from self-renewal to differentiation [38].
In our study, repression of Lin28 and of several let-7 target
mRNAs (4E-BP1, Sall4, Hmga2) was more pronounced in
LRRK2-deficient ES cells after retinoic acid treatment. Thus,
there is indirect evidence that lower protein levels of LRRK2 and
4E-BP1 in LRRK2+/2 ES cells may alleviate suppression of let-7
miRNA function thereby accelerating retinoic acid-induced
differentiation (Figure 8).
What may be the pathophysiological relevance of our find-
ingsindifferentiatingneuronstohumanParkinson’sdiseasepatients
carrying LRRK2 mutations? Although LRRK2 deficient/overex-
pressing mice do not exhibit a neurodegenerative phenotype,
LRRK2 deficiency/overexpression in immature neurons in culture
clearly affects neurite outgrowth [5,39]. Interestingly, in a
conditional transgenic mouse model of spinocerebellar ataxia type
1, expression of polyglutamine-expanded Ataxin-1 protein during
five days of cerebellar Purkinje cell development is sufficient for the
loss of motor coordination in adult mice [40]. Mutant Ataxin-1
destabilizes the transcription factor retinoic acid-related orphan
receptor alpha leading to a reduced expression of retinoic acid-
related orphan receptor alpha target genes that are critical for
Purkinje cell development. Thus, a short-term disturbance of a
retinoic acid receptor-coordinated neurodevelopmental program
can result in neuronal dysfunction in the adult brain even in the
absence of an immediate effect on neuronal phenotype. Besides its
role in the developing nervous system, retinoic acid signaling is also
required for maintenance of the nigrostriatal system [41]. The
dopamine D2 receptor promotor contains a functional retinoic acid
response element, and striatal D1/D2 receptor levels are reduced in
retinoic acid receptor knock-out mice. Adult knock-out mice exhibit
locomotor impairments in the absence of neuronal cell loss
indicating that retinoic acid signaling defects may contribute to
human PD [42]. Interestingly, knock-in mice expressing the PD-
linked LRRK2(R1441C) mutation show impaired locomotor
responses to the D2 receptor agonist quinpirole while the numbers
and morphology of nigral dopaminergic neurons are unchanged
[43]. Our gene expression profiling of basal ganglia tissue isolated
from LRRK2 knock-out mouse brain did not reveal significant
(adjusted p-value.0.05) changes in dopamine receptor mRNA
expression compared to wildtype littermates. Altered expression of
dopamine receptors however, may be restricted to subpopulations
of neurons within single brain nuclei as has recently been shown in
retinoid6receptor deficient mice [44]. Importantly, we detected an
increased number of hippocampal neural progenitor cells in our
LRRK2-deficient mice, while proliferation and survival of the
hippocampal stem cell population was unchanged. Retinoic acid
receptor signaling has been shown to influence neural precursor cell
numbers in the mouse brain [41] indicating in vivo relevance of our
findings in LRRK2+/2 ES cells. Moreover, impairment of
hippocampal neurogenesis has been described in animal models
of memory loss and depression [45] suggesting that mutant LRRK2
may also contribute to non-motor symptoms of PD.
Supporting Information
Figure S1 Southern Blot analysis of genomic DNA from
transfected ES cells detects homologous recombination of the
targeting vector at the mouse LRRK2 locus in six heterozygous ES
cell clones (15.3 kb) compared to wildtype cells (12.7 kb).
(TIF)
Figure S2 Ingenuity canonical pathway analysis of differentially-
expressed mRNAs identified by microarray gene expression
profiling. Significantly (p,0.005) enriched functional categories
are depicted according to their p-value. The orange line indicates
the calculated ratios. Blue bars represent the negative decadic
logarithm of p-values based on Fisher’s exact test.
(TIF)
Figure S3 Representative figure showing that membranes were
routinely checked for protein load and protein transfer after
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stains for total protein.
(TIF)
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